J Genet Med.  2009 Jun;6(1):74-80.

Integrated Test for Screening in Down Syndrome as a Predictor of Adverse Pregnancy Outcomes

Affiliations
  • 1Department of Obstetrics and Gynecology, College of Medicine, CHA General Hospital, CHA University, Korea. dockang@hotmail.com
  • 2Department of Clinical Chemistry, CHA General Hospital, CHA University, Seoul, Korea.

Abstract

PURPOSE
To assess the value of first-trimester pregnancy-associated plasma protein-A (PAPP-A), nuchal translucency (NT) and second-trimester alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), unconjugated estriol (uE3), and inhibin-A in predicting pregnancy complications other than fetal aneuploidy.
MATERIALS AND METHODS
A retrospective study in 3,121 singleton pregnancies with integrated testing was performed at Kangnam CHA hospital between January 2005 and December 2006. Baseline characteristics, pregnancy outcomes, and serum marker levels were obtained by review of the medical records. We analyzed the data to identify associations between the integrated screening markers and adverse pregnancy outcomes. Statistical analyses were performed with the SPSS program.
RESULTS
In preterm labor and preeclampsia, high AFP, hCG, and inhibin-A levels and low PAPP-A and NT levels were found to be significantly correlated (P<0.05). Elevated second-trimester inhibin- A levels were associated with preeclampsia (odds ratio 2.843), low birth weight (odds ratio 1.446), and preterm labor (odds ratio 1.287), and while decreased first-trimester PAPP-A levels were associated with preeclampsia (odds ratio 0.51) and preterm labor (odds ratio 0.75).
CONCLUSION
First- and second-trimester maternal serum markers screening can be used for predicting high-risk pregnancies.

Keyword

Prenatal diagnosis; Down syndrome screen; Maternal serum markers; Adverse pregnancy outcomes; Pregnancy complication; Preterm labor; Preeclampsia
Full Text Links
  • JGM
Share
  • Twitter
  • Facebook
Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr